# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Elizabeth I (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-RE003-SYN
- Date: 2026-02-23
- Fictional facility: St. Posthumous Health Center
- Fictional author: Philippa Ashcombe-Nwosu, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Four-week depression treatment review. **S**

## History of present illness

Ms. Tudor returns four weeks after starting sertraline: one week at 25 mg, then 50 mg each morning for three weeks. The sore throat she had three weeks ago cleared within a week. She has had no nausea, diarrhea, headache, tremor, dizziness, or bruising and has missed no doses. Her first interpersonal psychotherapy session took place two weeks after the referral rather than in the first week, because private end-of-day sessions had to be found; she has now had three. She sleeps about five hours, keeps the sleep window, and rarely naps. She eats three small meals and the supplement twice a day. She has held two audiences this week and has begun to take some pleasure in the gardens again, though she still feels heavy most mornings. She has had no thoughts of death or of harming herself. The dentist has taken impressions for a new partial denture. **S**

| Element | Detail |
|---|---|
| Medication | Sertraline 50 mg for three weeks after a week at 25 mg; no side effects |
| Psychotherapy | Three IPT sessions; the first was two weeks after referral |
| Sleep | About five hours; Insomnia Severity Index 14 |
| Function | Two audiences this week; some pleasure in the gardens |
| Safety | No suicidal thoughts |
| PHQ-9 | 13, down from 17 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Appetite a little better; weight 52.3 kg |
| Gastrointestinal | Negative | No nausea, diarrhea, or bleeding |
| Neurological | Negative | No headache, dizziness, or tremor |
| Psychiatric | Positive | Mood heavy in the mornings but lifting; no suicidal thoughts, elevated mood, or agitation |

4 systems reviewed. **S**

## Current medications

- Sertraline 50 mg oral tablet, one tablet by mouth each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/74 mmHg; pulse 74 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 52.3 kg; BMI 19.7 kg/m². All vital signs are synthetic.

Sodium: 136 mmol/L; PHQ-9: 13; GDS-15: 8. All results are synthetic.

## Change since baseline

- Sodium: 139 mmol/L at baseline, 136 mmol/L at this visit **S**
- PHQ-9: 17 at baseline, 13 at this visit **S**
- GDS-15: 10 at baseline, 8 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Thin; better color |
| Mental status | Engaged; speech at a more normal pace; mood "less heavy"; affect brighter at times; no suicidal ideation; no psychotic features |
| Cardiovascular | Blood pressure 124/74 mmHg seated and 120/72 mmHg standing; pulse 74 |
| Musculoskeletal | Timed Up and Go 11 seconds |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Major depressive disorder, single episode, moderate** (F32.1). PHQ-9 13, 24 percent below baseline, and GDS-15 8, after four weeks of sertraline and three weeks at 50 mg: early improvement, as expected at this point. Sodium 136 mmol/L, normal. No side effects; no suicidal thoughts. **S**
   - Continue sertraline 50 mg; review in three weeks.
   - If the PHQ-9 has not fallen by at least 50 percent after six to eight weeks at 50 mg, increase to 75 mg.
   - Continue weekly IPT.
   - Safety plan unchanged; 988 Suicide & Crisis Lifeline confirmed.
2. **Acute viral pharyngitis** (J02.9). Resolved within a week without antibiotics. **S**
   - No further action.
3. **Chronic insomnia comorbid with depression** (G47.00). Insomnia Severity Index 14, down from 19; sleep efficiency up on the diary. **S**
   - Widen the sleep window by 15 minutes, to 12:45 am to 6:30 am.
4. **Fall risk** (Z91.81). No falls; no orthostatic drop; Timed Up and Go 11 seconds. **S**
   - Continue the balance class.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PHQ-9 | Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 13, down from 17 (24 percent); item 9 scored 0 |
| Survey | GDS-15 | Baseline and to monitor response in adults 65 or older (monthly here) | Completed today | 8, down from 10 |
| Survey | Suicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9) | Every visit during active treatment | Completed today | No suicidal thoughts, intent, plan, or behavior; PHQ-9 item 9 scored 0; safety plan unchanged |
| Laboratory | Sodium after starting an SSRI in an older adult | About 2 to 4 weeks after starting | Completed today | 136 mmol/L, normal |
| Medication safety | SSRI tolerability check two weeks after the dose change | 2 weeks after starting and after each dose change | Deferred | Missed: the increase to 50 mg was made at the sick visit, and no contact was booked two weeks later; the first review at that dose is today, three weeks on. No harm: she has had no side effects, falls, or bleeding, and sodium is normal. Corrective action: a nurse telephone check is now booked two weeks after every antidepressant dose change |
| Medication safety | Adherence and adverse-effect review | Every visit during active treatment | Completed today | No missed doses; no nausea, headache, tremor, dizziness, or bruising |
| Referral | Interpersonal psychotherapy | Weekly from referral | Deferred | Late start: the first session was two weeks after the referral, not within the first week, because private end-of-day sessions had to be found. Outcome: three sessions so far, and the PHQ-9 is falling. Corrective action: the clinic now holds two end-of-day psychotherapy slots each week for patients who need privacy |
| Examination | Weight and nutrition | Every visit while weight is below her usual | Completed today | 52.3 kg, up 0.2 kg from the last visit; supplement twice a day |
| Examination | Fall risk on an SSRI: orthostatic blood pressure, gait, and falls since the last visit | At baseline, after starting an SSRI, and with dose changes | Completed today | No falls; no orthostatic drop; Timed Up and Go 11 seconds |
| Self-management | Sleep (CBT-I), activity, and social contact | Every visit during active treatment | Completed today | Insomnia Severity Index 14; sleep window widened; two audiences held; walks most days |
| Laboratory | Lithium, anticonvulsant, or antipsychotic monitoring (levels, metabolic tests, AIMS) | Only on those drugs | Not indicated | Treated with an SSRI only |

## Goal progress

- Medical causes of low mood and weight loss excluded by the second visit. Outcome by 2026-01-26: Blood count, metabolic panel, calcium, albumin, TSH, vitamin B12, folate, and MoCA normal; diphenhydramine stopped. **S**
- Response (PHQ-9 down by at least 50 percent) by twelve weeks of treatment, then remission (PHQ-9 below 5). In progress; target 2026-04-20. **S**
- No passive or active suicidal thoughts. Outcome by 2026-01-26: Passive death wish at intake only; PHQ-9 item 9 scored 0 from the second visit. **S**
- Sleep at least six hours most nights without hypnotics. In progress; target 2026-04-20. **S**
- Weight back to at least 55 kg, with a comfortable denture. In progress; target 2026-06-15. **S**

## Medication changes

- Stopped: Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for throat pain or fever, no more than 3 g a day **S**

## Guideline basis

- APA Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts (2019), American Psychological Association
- VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge
- American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults (2023), American Geriatrics Society (Journal of the American Geriatrics Society)
- Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians (2016), American College of Physicians (Annals of Internal Medicine)

## Follow-up

- Depression review in three weeks; her wellness visit is booked for next week. **S**
- Next scheduled visit 2026-03-02: subsequent annual wellness visit. **S**
